Inscrição na biblioteca: Guest
Journal of Environmental Pathology, Toxicology and Oncology

Publicou 4 edições por ano

ISSN Imprimir: 0731-8898

ISSN On-line: 2162-6537

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.4 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.8 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.5 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00049 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.59 SJR: 0.429 SNIP: 0.507 CiteScore™:: 3.9 H-Index: 49

Indexed in

Epidemiological and Clinical Aspects of Nonsteroidal Anti-inflammatory Drugs and Cancer Risks

Volume 21, Edição 2, 2002, 9 pages
DOI: 10.1615/JEnvironPatholToxicolOncol.v21.i2.130
Get accessGet access

RESUMO

It is well known that about 70% of cancer cases are due to environmental, dietary, or lifestyle factors. Accordingly, these cases may be avoided by appropriate modifications. In addition, active chemoprevention has become a major interventional approach following the epidemiological observation of a beneficial effect of nonsteroidal anti-inflammatory drugs (NSAIDs) in colon cancer prevention. This is chiefly due to the inhibition of the cyclooxygenase (COX) enzymes. The COX enzymatic system includes two isoenzymes, COX-1 and COX-2, that convert arachidonic acid to prostaglandins. COX-1 is constitutively expressed and synthesizes cytoprotective prostaglandins in the gastrointestinal tract. COX-2 is inducible by the oncogenes ras and scr and other cytokines; it is overexpressed in human cancer cells in which it stimulates cellular division and angiogenesis and inhibits apoptosis. NSAIDs restore apoptosis and decrease tumor mitogenesis and angiogenesis. Most cancer cells have been found to exhibit overexpression of COX-2.

CITADO POR
  1. Krishnan Aruna V., Trump Donald L., Johnson Candace S., Feldman David, The Role of Vitamin D in Cancer Prevention and Treatment, Endocrinology and Metabolism Clinics of North America, 39, 2, 2010. Crossref

  2. Koul Ashwani, Ghara Abdollah Ramzani, Gangar Subhash Chander, Chemomodulatory effects ofAzadirachta indica on the hepatic status of skin tumor bearing mice, Phytotherapy Research, 20, 3, 2006. Crossref

  3. Pogoda Janice M., Katz Jonathan, McKean-Cowdin Roberta, Nichols Peter W., Ross Ronald K., Preston-Martin Susan, Prescription drug use and risk of acute myeloid leukemia by French-American-British subtype: Results from a Los Angeles County case-control study, International Journal of Cancer, 114, 4, 2005. Crossref

  4. Nasir Aejaz, Kaiser Hans E., Boulware David, Hakam Ardeshir, Zhao Helena, Yeatman Timothy, Barthel James, Coppola Domenico, Cyclooxygenase-2 Expression in Right- and Left-Sided Colon Cancer: A Rationale For Optimization of Cyclooxygenase-2 Inhibitor Therapy, Clinical Colorectal Cancer, 3, 4, 2004. Crossref

  5. Vidal Sergio, Kovacs Kalman, Bell David, Horvath Eva, Scheithauer Bernd W., Lloyd Ricardo V., Cyclooxygenase-2 expression in human pituitary tumors, Cancer, 97, 11, 2003. Crossref

  6. Canby-Hagino Edith D, Thompson Ian M, Mechanisms of Disease: prostate cancer—a model for cancer chemoprevention in clinical practice, Nature Clinical Practice Oncology, 2, 5, 2005. Crossref

  7. Sorenmo K. U., Goldschmidt M. H., Shofer F. S., Goldkamp C., Ferracone J., Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma, Veterinary and Comparative Oncology, 2, 1, 2004. Crossref

  8. Kale Mruganka, Ramsey-Goldman Rosalind, Gordon Caroline, Clarke Ann E, Bernatsky Sasha, Malignancies in systemic lupus erythematosus, International Journal of Clinical Rheumatology, 8, 2, 2013. Crossref

  9. Gangar Subhash Chander, Koul Ashwani, Azadirachta indicamodulates carcinogen biotransformation and reduced glutathione at peri-initiation phase of benzo(a)pyrene induced murine forestomach tumorigenesis, Phytotherapy Research, 22, 9, 2008. Crossref

  10. DiNicolantonio James J., McCarty Mark F., Chatterjee Subhankar, Lavie Carl J., O’Keefe James H., A Higher Dietary Ratio of Long-Chain Omega-3 to Total Omega-6 Fatty Acids for Prevention of COX-2-Dependent Adenocarcinomas, Nutrition and Cancer, 66, 8, 2014. Crossref

  11. Lee Ki Won, Lee Hyong Joo, The roles of polyphenols in cancer chemoprevention, BioFactors, 26, 2, 2006. Crossref

  12. Varney Michelle L., Singh Rakesh K., The Role of Inflammation in Tumor Progression: Targeting Tumor-Associated Macrophages, Clinical Research and Regulatory Affairs, 25, 3, 2008. Crossref

  13. Chen Xiao Yun, Park Seong Jun, Buschmann Helmut, De Rosa Maria, Bolm Carsten, Syntheses and biological activities of sulfoximine-based acyclic triaryl olefins, Bioorganic & Medicinal Chemistry Letters, 22, 13, 2012. Crossref

  14. Smith D. L. H., Keshavan P., Avissar U., Ahmed K., Zucker S. D., Sodium taurocholate inhibits intestinal adenoma formation in APCMin/+ mice, potentially through activation of the farnesoid X receptor, Carcinogenesis, 31, 6, 2010. Crossref

  15. Dai Zhi-jun, Wang Xi-jing, Liu Xiao-xu, Kang Hua-feng, Jiang Jina-tao, Guan Hai-tao, Zhang Shu-qun, Xue Xing-huan, Xue Feng-jie, Up-regulation of cyclooxygenase-2 gene expression correlates with tumor angiogenesis in human breast cancer, Chinese Journal of Cancer Research, 15, 2, 2003. Crossref

  16. Uray Ivan P, Brown Powel H, Prevention of breast cancer: current state of the science and future opportunities, Expert Opinion on Investigational Drugs, 15, 12, 2006. Crossref

  17. Endo Satoshi, Matsunaga Toshiyuki, Soda Midori, Tajima Kazuo, Zhao Hi-Tai, El-Kabbani Ossama, Hara Akira, Selective Inhibition of the Tumor Marker AKR1B10 by Antiinflammatory N-Phenylanthranilic Acids and Glycyrrhetic Acid, Biological and Pharmaceutical Bulletin, 33, 5, 2010. Crossref

  18. Bernatsky Sasha, Kale Mruganka, Ramsey-Goldman Rosalind, Gordon Caroline, Clarke Ann E., Systemic lupus and malignancies, Current Opinion in Rheumatology, 24, 2, 2012. Crossref

  19. Dai Yinmei, Zhang Xiangdong, Peng Yunhua, Wang Ziren, The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma, Gynecologic Oncology, 97, 1, 2005. Crossref

  20. Sooriakumaran P., Kaba R., The risks and benefits of cyclo-oxygenase-2 inhibitors in prostate cancer: A review, International Journal of Surgery, 3, 4, 2005. Crossref

  21. LEE KI WON, LEE HYONG JOO, LEE CHANG YONG, Vitamins, Phytochemicals, Diets, and Their Implementation in Cancer Chemoprevention, Critical Reviews in Food Science and Nutrition, 44, 6, 2004. Crossref

  22. Thompson Patricia A., Khatami Mahin, Baglole Carolyn J., Sun Jun, Harris Shelley A., Moon Eun-Yi, Al-Mulla Fahd, Al-Temaimi Rabeah, Brown Dustin G., Colacci Anna Maria, Mondello Chiara, Raju Jayadev, Ryan Elizabeth P., Woodrick Jordan, Scovassi A.Ivana, Singh Neetu, Vaccari Monica, Roy Rabindra, Forte Stefano, Memeo Lorenzo, Salem Hosni K., Amedei Amedeo, Hamid Roslida A., Lowe Leroy, Guarnieri Tiziana, Bisson William H., Environmental immune disruptors, inflammation and cancer risk, Carcinogenesis, 36, Suppl 1, 2015. Crossref

  23. Polyak Kornelia, Haviv Izhak, Campbell Ian G., Co-evolution of tumor cells and their microenvironment, Trends in Genetics, 25, 1, 2009. Crossref

  24. Zha Shan, Yegnasubramanian Vasan, Nelson William G., Isaacs William B., De Marzo Angelo M., Cyclooxygenases in cancer: progress and perspective, Cancer Letters, 215, 1, 2004. Crossref

  25. Liu Su-Fang, Wang Hai, Li Zi-Jian, Deng Xi-Yun, Xiang Hui, Tao Yong-Guang, Li Wei, Tang Min, Cao Ya, Aspirin induces lytic cytotoxicity in Epstein–Barr virus-positive cells, European Journal of Pharmacology, 589, 1-3, 2008. Crossref

  26. Lynch Henry, Shaw Trudy, Lynch Jane, Roy Hemant, Nonsteroidal Anti-Inflammatory Drugs (NSAID) and Colorectal Cancer, in Phytopharmaceuticals in Cancer Chemoprevention, 20041296, 2004. Crossref

  27. Yu Yunxian, Zhang Mingwu, Pan Yifeng, Jin Mingjuan, Jiang Xia, Zhang Shanchun, Wu Yinyin, Ni Qun, Li Qilong, Chen Kun, PLA2G4A mutants modified protective effect of tea consumption against colorectal cancer, International Journal of Colorectal Disease, 27, 8, 2012. Crossref

  28. Hussain Tajamul, Gupta Sanjay, Mukhtar Hasan, Cyclooxygenase-2 and prostate carcinogenesis, Cancer Letters, 191, 2, 2003. Crossref

  29. Queiroga F.L., Alves A., Pires I., Lopes C., Expression of Cox-1 and Cox-2 in Canine Mammary Tumours, Journal of Comparative Pathology, 136, 2-3, 2007. Crossref

  30. Mahkonen Anna, Putaala Heli, Mustonen Harri, Rautonen Nina, Puolakkainen Pauli, Lactobacillus acidophilus74-2 and Butyrate Induce Cyclooxygenase (COX)-1 Expression in Gastric Cancer Cells, Immunopharmacology and Immunotoxicology, 30, 3, 2008. Crossref

  31. Huang Dong-Sheng, Specific COX-2 inhibitor NS398 induces apoptosis in human liver cancer cell line HepG2 through BCL-2, World Journal of Gastroenterology, 11, 2, 2005. Crossref

  32. JACOBO-HERRERA NADIA J., PÉREZ-PLASENCIA CARLOS, CAMACHO-ZAVALA ELIZABETH, GONZÁLEZ GABRIELA FIGUEROA, URRUTIA EDUARDO LÓPEZ, GARCÍA-CASTILLO VERÓNICA, ZENTELLA-DEHESA ALEJANDRO, Clinical evidence of the relationship between aspirin and breast cancer risk (Review), Oncology Reports, 32, 2, 2014. Crossref

  33. Schrör Karsten, Mehta Paulette, Mehta Jawahar L., Cardiovascular Risk of Selective Cyclooxygenase-2 Inhibitors, Journal of Cardiovascular Pharmacology and Therapeutics, 10, 2, 2005. Crossref

  34. Moloney Jennifer N., Cotter Thomas G., ROS signalling in the biology of cancer, Seminars in Cell & Developmental Biology, 80, 2018. Crossref

  35. Hughes-Fulford Millie, Tjandrawinata Raymond R., Li Chai-Fei, Sayyah Sina, Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A 2 in prostate carcinoma cells, Carcinogenesis, 26, 9, 2005. Crossref

  36. Feng Dingqing, Zhao Tingting, Yan Keqin, Liang Haiyan, Liang Jing, Zhou Ying, Zhao Weidong, Ling Bin, Gonadotropins promote human ovarian cancer cell migration and invasion via a cyclooxygenase 2-dependent pathway, Oncology Reports, 38, 2, 2017. Crossref

  37. Ding Haiming, Han Chunhua, Gibson-D?Ambrosio Ruth, Steele Vernon E., D?Ambrosio Steven M., Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1, International Journal of Cancer, 107, 5, 2003. Crossref

  38. BARQAWI ALBAHA, THOMPSON IAN M., CRAWFORD E. DAVID, Prostate Cancer Chemoprevention: An Overview of United States Trials, Journal of Urology, 171, 2S, 2004. Crossref

  39. Lam Anna N. C., Demasi Maryanne, James Michael J., Husband Alan J., Walker Catherine, Effect of Red Clover Isoflavones on Cox-2 Activity in Murine and Human Monocyte/Macrophage Cells, Nutrition and Cancer, 49, 1, 2004. Crossref

  40. Grab Leslie T, Kearns Mary W, Morris Andrew J, Daniel Larry W, Differential role for phospholipase D1 and phospholipase D2 in 12-O-tetradecanoyl-13-phorbol acetate-stimulated MAPK activation, Cox-2 and IL-8 expression, Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 1636, 1, 2004. Crossref

  41. Polychronis N.M., Banti C.N., Raptopoulou C.P., Psycharis V., Kourkoumelis N., Hadjikakou S.K., Non steroidal anti-inflammatory drug (NSAIDs) in breast cancer chemotherapy; antimony(V) salicylate a DNA binder, Inorganica Chimica Acta, 489, 2019. Crossref

  42. Shao Xue-jing, Xiang Sen-feng, Chen Ying-qian, Zhang Ning, Cao Ji, Zhu Hong, Yang Bo, Zhou Qian, Ying Mei-dan, He Qiao-jun, Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells, Acta Pharmacologica Sinica, 40, 10, 2019. Crossref

  43. Surh Young-Joon, Chemopreventive Phenolic Compounds in Common Spices, in Carcinogenic and Anticarcinogenic Food Components, 20054980, 2005. Crossref

  44. Fisher Oliver M., Lord Reginald V.N., Epidemiology of Barrett Esophagus and Risk Factors for Progression, in Shackelford's Surgery of the Alimentary Tract, 2 Volume Set, 2019. Crossref

  45. Núñez Troconis José, Chlamydia trachomatis. Co-factor or factor in cancer of the cervix?, Investigación Clínica, 62, 3, 2021. Crossref

  46. Vrontaki E., Leonis G., Papadopoulos M. G., Simcic M., Grdadolnik S. Golic, Afantitis A., Melagraki G., Hadjikakou S. K., Mavromoustakos T., Comparative Binding Effects of Aspirin and Anti-Inflammatory Cu Complex in the Active Site of LOX-1, Journal of Chemical Information and Modeling, 52, 12, 2012. Crossref

  47. Krishnan Aruna V., Feldman David, Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin D, Annual Review of Pharmacology and Toxicology, 51, 1, 2011. Crossref

  48. Goncharova Roza I, Kuzhir Tatyana D, Molecular basis of applying antimutagens as anticarcinogens, Ecological genetics, 3, 3, 2005. Crossref

  49. Müller Arndt-Christian, Handrick René, Elsaesser Simon Johannes, Rudner Justine, Henke Guido, Ganswindt Ute, Belka Claus, Jendrossek Verena, Importance of Bak for celecoxib-induced apoptosis, Biochemical Pharmacology, 76, 9, 2008. Crossref

  50. Pruthi Raj S., Derksen J. Eric, Moore Dominic, Carson Culley C., Grigson Gayle, Watkins Cathy, Wallen Eric, Phase II Trial of Celecoxib in Prostate-Specific Antigen Recurrent Prostate Cancer after Definitive Radiation Therapy or Radical Prostatectomy, Clinical Cancer Research, 12, 7, 2006. Crossref

  51. Longo Valter D., Finch Caleb E., Evolutionary Medicine: From Dwarf Model Systems to Healthy Centenarians?, Science, 299, 5611, 2003. Crossref

  52. Anderson Lesley A., Johnston Brian T., Watson R.G. Peter, Murphy Seamus J., Ferguson Heather R., Comber Harry, McGuigan Jim, Reynolds John V., Murray Liam J., Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence, Cancer Research, 66, 9, 2006. Crossref

  53. Krishnan Aruna V., Feldman David, Anti-inflammatory Activity of Calcitriol in Cancer, in Vitamin D and Cancer, 2011. Crossref

  54. Poyraz M., Banti C.N., Kourkoumelis N., Dokorou V., Manos M.J., Simčič M., Golič-Grdadolnik S., Mavromoustakos T., Giannoulis A.D., Verginadis I.I., Charalabopoulos K., Hadjikakou S.K., Synthesis, structural characterization and biological studies of novel mixed ligand Ag(I) complexes with triphenylphosphine and aspirin or salicylic acid, Inorganica Chimica Acta, 375, 1, 2011. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain